Xeris Biopharma Holdings（NASDAQ: XERS）报告季度每股亏损$0.03，优于分析师预期的$0.06，增幅为50%。相比去年同期每股亏损$0.10，本季度亏损减少了70%。公司报告季度销售额为$60.10M，优于分析师预期的$58.10M，增幅为3.43%。相比去年同期的$44.39M，本季度销售额增长了35.39%。

以上内容来自Benzinga Earnings专栏，原文如下：

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 70 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $60.10 million which beat the analyst consensus estimate of $58.10 million by 3.43 percent. This is a 35.39 percent increase over sales of $44.39 million the same period last year.